Providing Communicative/Evidence-Based Integrative Kidney Cancer Care

Video

According to an expert from University Hospitals, integrative oncology has a place in the treatment of patients with kidney cancer alongside palliative care, psycho-oncology, and physical therapy.

CancerNetwork® spoke with Santosh Rao, MD, in an interview during Kidney Cancer Awareness Month 2023 about how integrative oncology fits into multidisciplinary care strategies along with surgical, radiation, and medical oncology for patients with kidney cancer.

Rao, medical director of integrative oncology for University Hospitals Connor Whole Health and president-elect for the Society for Integrative Oncology, also indicated that integrative oncology consults are important tools for guiding patients using strong communication and evidence-based methods.

Transcript:

We have to think creatively. When I think of multidisciplinary care, it’s obviously [disciplines such as] surgical, radiation, and medical oncology which includes chemotherapy and immunotherapy. And you look for the issues that can come up throughout that whole journey. I don’t think of it as just integrative oncology. Integrative oncology is a broad term that involves a lot of different things.

But it has a certain place which can be alongside palliative care, psycho-oncology, and physical therapy. All these different things that we employ such as social work affect all patients with cancer in some ways or another at different times. Kidney cancer is no different. If you [have] depression, for example, what are the resources that can really help someone? That’s really the way I think about it.

The other thing we didn’t talk about is that many people have a lot of questions. One of the things that I do is integrative oncology consults. We will look at someone’s lifestyle and how they manage their stress, and we’ll also talk about questions that they have and what supplements and natural products they’re using.

That, as we’ve seen, is a huge business. Many people have all sorts of important questions, but if you don’t have any guidance, people are just going online and reading stuff. And we know that they don’t always bring it up with their physician. Also, many people don’t understand what to tell patients [about] what [products are] safe, not safe, et cetera. That’s important too. Whether you’re treating kidney cancer or another cancer, it comes up. Getting good guidance, communicating and collaborating, and doing it in an evidence-based way is also important.

Recent Videos
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Related Content